Pancreatic Cancer Research

ResearcherLanzhou University Second HospitalActive in the last 2 years

Pengxian Tao

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0001-8286-7430; OpenAlex author ID A5081781827. Sources: OpenAlex.

Their work

Papers
4
Trials
0
Grants
0
Labs led
0
Collaborators
10
Papers, trials and grants by year

2020: 1 paper · 2021: 1 paper · 2022: none · 2023: 1 paper · 2024: none · 2025: none · 2026: 1 paper

Papers 4

  1. DLGAP5 enhances chemotherapy resistance in pancreatic ductal adenocarcinoma by regulating glycolysis through MYC. Co-author DOI 10.1016/j.cellsig.2026.112841↗
  2. Pan‑cancer analysis identified ARHGAP23 as a potential biomarker for pancreatic adenocarcinoma. Co-author DOI 10.3892/mco.2023.2696↗
  3. Advances and challenges of neoadjuvant therapy in pancreatic cancer. Co-author DOI 10.1111/ajco.13504↗
  4. Prognostic significance of tissue factor in patients with pancreatic cancer: a systematic review protocol. Co-author DOI 10.1136/bmjopen-2020-037431↗

Closest collaborators

The 10 strongest of 10 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Hui Cai · 1 shared paper, 2026 · strength 0.36
  2. Yang Yu · 2 shared papers, 2020–2021 · strength 0.21
  3. Xin Li · 1 shared paper, 2023 · strength 0.20
  4. Yulan Li · 1 shared paper, 2023 · strength 0.20
  5. Xiaolong Liu · 1 shared paper, 2023 · strength 0.20
  6. Dan Wang · 1 shared paper, 2021 · strength 0.12
  7. Hao Chen · 1 shared paper, 2021 · strength 0.12
  8. Tao Zhang · 1 shared paper, 2020 · strength 0.09
  9. Hao Chen · 1 shared paper, 2020 · strength 0.09
  10. Haiyuan Li · 1 shared paper, 2020 · strength 0.09

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.